Your browser doesn't support javascript.
loading
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.
Khanam, Razwana; Shahzad, Moazzam; Chaudhary, Sibgha Gull; Ali, Fatima; Shah, Zunairah; Pachika, Pranali S; Ahmed, Zahoor; Chattaraj, Asmi; Masood, Adeel; Ahmed, Nausheen; Bansal, Rajat; Balusu, Ramesh; Shune, Leyla; Anwar, Faiz; Hematti, Peiman; McGuirk, Joseph P; Yacoub, Abdulraheem; Mushtaq, Muhammad Umair.
Afiliação
  • Khanam R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Shahzad M; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Chaudhary SG; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Ali F; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Shah Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Pachika PS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Ahmed Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Chattaraj A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Masood A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Bansal R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Balusu R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Shune L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Anwar F; Division of Hematology/Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Hematti P; Division of Hematology/Oncology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
  • McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Yacoub A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Leuk Lymphoma ; 63(11): 2671-2678, 2022 Nov.
Article em En | MEDLINE | ID: mdl-35687838
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Antimetabólitos Antineoplásicos Tipo de estudo: Guideline / Observational_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Antimetabólitos Antineoplásicos Tipo de estudo: Guideline / Observational_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos